Scott Rocklage, Ph.D., Chairman of the Board
Dr. Rocklage joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. Dr. Rocklage has over three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan™, Teslascan® and Cubicin®), and he has entered multiple drug candidates into clinical trials. Dr. Rocklage has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar, and has also held various R&D positions at Salutar and Catalytica. Dr. Rocklage currently serves as Board Chairman of Rennovia, Kinestral and Cidara as well as on the Boards of Achaogen, Pulmatrix, and Epirus. Dr. Rocklage was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed) and Semprus (acquired by Teleflex). Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his PhD in Chemistry from the Massachusetts Institute of Technology where he conducted research in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005).
Mr. Burgess has more than 20 years of executive level experience in the biotechnology and pharmaceutical industries. In 2011, he was one of the founding members of Rempex, which was subsequently acquired by The Medicines Co. in 2013 for $140M upfront, with a total potential deal value of $474M. Prior to Rempex, Mr. Burgess was President and CEO of Mpex Pharmaceuticals, which he joined in 2007. During his tenure as CEO, Mpex advanced its lead product Aeroquin from Phase 1 into Phase 3 clinical trials, raised substantial venture capital funding and ultimately achieved a successful exit in 2011 with its acquisition by Aptalis. The transaction with Aptalis was named by Scrip magazine as a finalist for “Deal of the Year”. Before joining Mpex, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, Inc., a publicly traded biotechnology company focused on biodefense, infectious disease and immune system disorders. Previously, he spent ten years at Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited), a specialty pharmaceutical firm, where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess received his BA in Economics from Stanford University and an MBA from Harvard Business School. Mr. Burgess was a member of the Board of Directors of Santarus, Inc. until its acquisition by Salix for $2.6B in 2013.
Timothy Franson, M.D.
Dr. Franson has served as the chief medical officer of YourEncore, an advisory firm focused on global life sciences and consumer health companies, since May 2014. From 2009 until May 2014, he was a principal of FaegreBD Consulting, a clinical and regulatory pharmaceutical development consulting firm, and currently maintains a relationship with FaegreBD through its strategic alliance with YourEncore. From 2008 until 2009, Dr. Franson served as the founder and president of Franson PharmaAdvisors LLC, a clinical and regulatory pharmaceutical development consulting firm. Prior to assuming these roles, Dr. Franson was vice president of Global Regulatory Affairs at Lilly Research Laboratories, a part of Eli Lilly and Company, which he joined in 1986. Dr. Franson is integrally involved in global public health initiatives through the US Pharmacopeial Convention (USP), currently serving as the president of this organization and on the executive committee of the USP Board of Trustees. He serves on the Board of Directors of Paratek Pharmaceuticals and the Critical Path Institute, which collaborates with FDA and industry in innovation advances. Dr. Franson has authored more than 50 articles in the fields of infectious disease, epidemiology, pharmacoeconomics, and antibiotic utilization. He holds a B.S. in pharmacy from Drake University and an M.D. from the University of Illinois College of Medicine. He is board certified in Internal Medicine and Infectious Diseases.
David Gollaher, Ph.D.
Dr. Gollaher served as the head of global government affairs and policy for Gilead Sciences from early 2014 to mid-2018, a period during which the company launched a breakthrough cure for hepatitis C (HCV) and tripled revenues from $10 billion to $30 billion. In addition to the introduction of three novel drugs for HCV, building on Gilead’s strength in virology, he was involved in the launch of a new generation of medicines for HIV/AIDS. Before joining Gilead, Dr. Gollaher was co-founder and CEO of the California Healthcare Institute (CHI). From 1993 to 2013 he built CHI into the nation’s premier state-based life sciences policy research and advocacy association, with offices in Washington D.C. and Sacramento, representing some 370 biopharma, medical device and diagnostics companies, along with leading academic institutions, venture capital and professional services firms. In 2018, Dr. Gollaher was appointed a Senior Fellow at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California. He currently serves on Gilead’s Health Policy Advisory Board and the Board of Overseers for The Scripps Research Institute. Earlier in his career, Dr. Gollaher was vice president at Scripps Clinic and Research Foundation, responsible for managed care, strategy and corporate affairs. He earned his B.A. from UCSB and his master’s and Ph.D. degrees, concentrating in the history of science and medicine, from Harvard University.
Ms. Mineo led corporate development at Receptos, Inc., from 2009 to 2015, where strategic partnering efforts for Phase 3 immunology candidate ozanimod resulted in the company’s acquisition by Celgene. During her tenure she played a key role in the Receptos initial public offering (IPO) and established product and technology collaborations with AbbVie, Ono, Lilly and Janssen. Prior to Receptos, Ms. Mineo held roles of increasing business development responsibility at Neurocrine Biosciences from 1997 to 2009, where she led or played a primary role in negotiating and closing more than 25 transactions, including worldwide or regional product candidate collaborations from Phase 1 to registration and product in-licensing transactions. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen, DNAX Research Institute, Schering Plough and Baxter Biotech. Ms. Mineo holds a B.S. in Zoology from the University of California, Davis and received her M.B.A. from Duke University’s Fuqua School of Business.
Mr. Schroeder is currently Chief Executive Officer and a director of Nabriva Pharmaceuticals, a role he has held subsequent to the 2018 acquisition of Zavante Therapeutics where Mr. Schroeder was President and CEO. Prior to that he was one of Cadence Pharmaceutical’s co-founders and served as President and Chief Executive Officer and as a member of the board of directors since their inception in May 2004 until their acquisition by Mallinckrodt for $1.4B in 2014. From August 2002 to February 2004, he served as Senior Vice President of North America Sales and Marketing of Elan Pharmaceuticals, Inc., a neuroscience-based pharmaceutical company. From February 2001 to August 2002, Mr. Schroeder served as General Manager of the Hospital Products Business Unit at Elan, a position he also held at Dura Pharmaceuticals, Inc., a specialty respiratory pharmaceutical and pulmonary drug delivery company, from May 1999 to November 2000 until its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder is currently a member of the Board of Directors of Biocom, a regional life science trade association, where he is Chairman and a member of the executive committee. Mr. Schroeder is also a current director of Otonomy, Inc., and Collegium Pharmaceuticals. Previously Mr. Schroeder served on the boards of Cadence Pharmaceuticals, Incline Therapeutics, Hyperion Therapeutics and Trius Therapeutics until their respective acquisitions. Mr. Schroeder holds a B.S. in management from Rutgers University.
Jeffrey Stein, Ph.D., President and Chief Executive Officer
Dr. Stein has been President, CEO and Director of Cidara since January 2014. Previously he was CEO of Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration in June 2014. Tedizolid is now marketed by Merck under the name Sivextro. Dr. Stein currently serves as a Director of Paratek Pharmaceuticals (NASDAQ: PRTK) and Ideaya Biosciences. He is also founding Chairman and President of the Antimicrobials Working Group, an industry leading 501(c)(6) organization. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.